FFO
GDRX icon

Fortitude Family Office’s GoodRx Holdings GDRX Stock Holding History

Fortitude Family Office’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$13 – 1996
2025
Q3 		$13 Hold
3
– – ﹤0.01% 1973
2025
Q2 		$15 Buy
+3
New +$13 ﹤0.01% 2022

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

Fortitude Family Office's GDRX Position: Q4 2025 in Review

Fortitude Family Office sold out of GoodRx Holdings (GDRX) in Q4 2025, closing a stake of 3 shares — an estimated $13 sold.

Fortitude Family Office first reported a position in GDRX in Q2 2025 and held it in 2 quarters. The position peaked at $15 in Q2 2025. 183 funds tracked by Wall St. Rank hold GDRX as of Q4 2025.

  • Fortitude Family Office reported no remaining GoodRx Holdings position as of Q4 2025 after selling out during the quarter.
  • Fortitude Family Office sold 3 GoodRx Holdings shares in Q4 2025, an estimated $13.
  • Fortitude Family Office first reported a position in GoodRx Holdings in Q2 2025 and held it in 2 quarters.
  • Fortitude Family Office's GoodRx Holdings position peaked at $15 in Q2 2025.
  • 183 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2025.

Based on Fortitude Family Office's 13F filing for Q4 2025, filed 15 Jan 2026.